HYBIO(SZ:300199)2022-12-06 09:46Product Overview - Cabergoline is a synthetic long-acting oxytocin analog approved for market in February 2016, aimed at preventing postpartum hemorrhage and enhancing uterine contractions [2] - The product's launch enriches the company's core product line and is expected to significantly boost company performance [2] Sales Performance - Terlipressin, a synthetic vasopressin analog, generated sales revenue of ¥68,370,177.72 in the first half of 2016, marking a 35.08% increase compared to the same period last year [3] - The company aims for a 50% revenue growth for Terlipressin by the end of the year through enhanced academic promotion and sales efforts [3] International Market Strategy - The company has a strong R&D capability in peptide drugs and aims to expand its international market presence, including in developed regions like the US, Europe, Japan, and South Korea, as well as emerging markets like India [3] - Plans include increasing overseas registration and market expansion efforts for peptide drugs and raw materials [3] Competitive Advantages - The company has invested 10 years in the R&D of Glatiramer and 7 years in Liraglutide, establishing a competitive edge in the international raw material drug market [4] - The company is recognized as a preferred supplier for major pharmaceutical companies, enhancing its market share and brand recognition [4] Recent Acquisitions and Growth - Following the acquisition of Chengji Pharmaceutical, the company has integrated its management and production systems, leading to significant revenue growth in combination packaging products (¥39,859,100, up 320.49%) and medical devices (¥53,301,000, up 259.29%) in the first half of 2016 [4] - Future plans include leveraging Chengji's production scale and cost advantages to expand sales and improve overall profitability [4]